NextCure : NXTC

NXTC

Stock Data

$2.02

$0.18 (8.18%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.

All NextCure Articles

3 Articles

Lee Jackson | Mar 5, 2021 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Autodesk, Costco, Interactive Brokers, SBA Communications, Western Digital, Zscaler and More

Friday's top analyst upgrades and downgrades included Autodesk, Costco, Gap, Interactive Brokers, SBA Communications, Smith & Wesson, Western Digital and…

Chris Lange | Nov 11, 2019 at 12:05 PM EST

Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment

NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As…

Jon C. Ogg | Sep 5, 2019 at 2:00 PM EDT

Is NextCure the Next Big Cancer Biotech Every Investor Missed?

NextCure appears to be one of those companies that has flown under the radar of the investing community since its…

NextCure : NXTC

NXTC

$2.02

All NextCure Articles

Top Analyst Upgrades and Downgrades: Autodesk, Costco, Interactive Brokers, SBA Communications, Western Digital, Zscaler and More

Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment

Is NextCure the Next Big Cancer Biotech Every Investor Missed?

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

NextCure : NXTC

NXTC

$2.02

All NextCure Articles

Top Analyst Upgrades and Downgrades: Autodesk, Costco, Interactive Brokers, SBA Communications, Western Digital, Zscaler and More

Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment

Is NextCure the Next Big Cancer Biotech Every Investor Missed?

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

Featured Reads

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings